Scientists Found the Deadliest Malaria Parasite Is Accumulating Resistance to Multiple Drugs

Malaria parasites are engaged in a relentless evolutionary arms race, rapidly adapting to survive the drugs designed to kill them. A new genetic study published in Nature Microbiology shows that Plasmodium falciparum, the deadliest malaria parasite, is accumulating resistance to multiple antimalarial drugs at the same time.

Researchers found that the parasite has retained resistance to medications abandoned years ago while simultaneously acquiring mutations that could weaken the effectiveness of today's frontline treatments.

Old antimalarial drugs still influence parasite evolution

Malaria continues to rank among the world's deadliest infectious diseases, causing hundreds of millions of infections and more than 600,000 deaths each year, most of them among young children in Africa.

Over the past seven decades, P. falciparum has evolved resistance to nearly every major antimalarial drug, including artemisinin-based therapies, which remain the cornerstone of treatment.

Although Ethiopia stopped using chloroquine against P. falciparum many years ago because of widespread resistance, the drug is still prescribed to treat Plasmodium vivax, a less severe malaria parasite that often circulates in the same regions.

Researchers wanted to determine whether this continued chloroquine use against P. vivax might still be shaping the evolution of P. falciparum.

How the study was conducted

Scientists sequenced major drug-resistance genes from 605 P. falciparum infections collected between 2019 and 2023 across 15 districts in Ethiopia.

The selected regions differed in malaria transmission intensity and in how frequently P. falciparum and P. vivax occurred together, allowing researchers to compare resistance patterns under different treatment pressures.

Resistance to discontinued drugs remains widespread

The analysis showed that genetic markers linked to chloroquine resistance remain remarkably common despite the drug's withdrawal for treating P. falciparum decades ago.

Among 492 successfully analyzed samples, 61.2% carried the characteristic chloroquine-resistance pattern, suggesting that ongoing chloroquine use against P. vivax continues to maintain these mutations.

Researchers observed a similar trend for sulfadoxine-pyrimethamine, another treatment that Ethiopia discontinued in 2005.

Resistance markers associated with this older drug combination appeared in 42.8% of 453 analyzed samples, demonstrating that genetic resistance can persist long after treatment policies change.

Frontline malaria therapies face increasing pressure

Artemether-lumefantrine remains Ethiopia's standard treatment for uncomplicated P. falciparum malaria.

Artemether rapidly kills most parasites, while lumefantrine eliminates those that remain, helping prevent treatment failure.

The researchers identified the main genetic marker associated with partial artemisinin resistance in 10% of 572 tested samples, with additional artemisinin-related mutations detected at lower frequencies.

In one district, however, the prevalence of the key resistance mutation reached 48.6%, highlighting substantial regional variation.

The situation was even more concerning for lumefantrine.

A genetic pattern linked to reduced sensitivity to lumefantrine appeared in 93% of 483 classified samples, suggesting that the partner drug in Ethiopia's first-line therapy is already under considerable evolutionary pressure.

Multiple resistance traits are appearing together

One of the study's most important findings was that resistance mutations are increasingly occurring in combination rather than independently.

Parasites carrying chloroquine-resistance markers were more than three times as likely to also possess markers associated with partial artemisinin resistance.

Researchers warn that this clustering of resistance traits raises the possibility that parasites could become increasingly difficult to eliminate using existing drug combinations.

Resistance differs across Ethiopia

The authors emphasize that the study examined genetic resistance markers rather than actual treatment failures.

Artemether-lumefantrine remains broadly effective in Ethiopia, but the genetic evidence suggests its long-term effectiveness cannot be assumed.

Instead of finding one nationwide resistance pattern, the researchers discovered a patchwork of parasite populations carrying different combinations of mutations depending on local drug use, malaria species distribution and transmission intensity.

This means malaria control strategies may need to be tailored to individual regions rather than relying on a single national approach.

Why ongoing surveillance is critical

The researchers argue that monitoring programs should track both P. falciparum and P. vivax, combining whole-genome sequencing with long-term clinical monitoring to detect emerging resistance before widespread treatment failure occurs.

Such surveillance could help health authorities update treatment policies earlier, evaluate alternative drug combinations and target high-risk districts with more intensive control measures.

As newer malaria tools—including the RTS,S and R21 vaccines—are introduced across Africa, the authors say they should complement, rather than replace, careful management of antimalarial drugs.

For now, Ethiopia's frontline treatments continue to work in most cases. However, the growing accumulation of resistance mutations suggests that preserving these medicines will require continuous monitoring and rapid responses as the parasite continues to evolve.